A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
Checked against the public recordLast updated Apr 22, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-00299804
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1; * Platelets \> 100,000, ANC \> 1500; * Ccr \> 60 or serum creat. \<1.5 * Non-small cell cancer cohort: * Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, \< 4 prior chemotherapy regimen * HgA1C \<5.7% Exclusion Criteria: * Active Central Nervous System (CNS) metastases; * prior IGF1-R targeted therapy * Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pfizer Investigational SiteAmherst, New York
- Pfizer Investigational SiteBuffalo, New York
- Pfizer Investigational SiteSan Antonio, Texas
- Pfizer Investigational SiteVillejuif
- Pfizer Investigational SiteMadrid
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 22, 2024. Always confirm current availability with the study team.